Document is current
Any future updates will be listed below
-
Authors
Misawa, Sonoko
Denda, Tadamichi
Kodama, Sho
Suzuki, Takuji
Naito, Yoichi
Kogawa, Takahiro
Takada, Mamoru
Suichi, Tomoki
Shiosakai, Kazuhito
Kuwabara, Satoshi
,
Saito, Go
Hino, Aoi
Imanishi, Shunsuke
Ureshino, Norio
Satomi, Daisuke
Tanabe, Yuko
Hanaoka, Yutaka
Miyamoto, Atsushi
Suzuki, Takeshi
Naganuma, Atsushi
Yanagita, Yasuhiro
Sekine, Katsutoshi
Kusano, Fumihiko
Nakamura, Masato
Imazeki, Hiroshi
- License Information
-
More Information
Article History
Received: 31 March 2023
Accepted: 23 October 2023
First Online: 11 November 2023
Change Date: 16 November 2023
Change Type: Update
Change Details: Additional file 1 is now accessible
Declarations
:
: The MiroCIP study was preapproved by the Chiba University Certified Clinical Research Review Board (CRB no. CRB3180015), which notified all participating centers of the approval.The study was carried out in accordance with the Clinical Research Act in Japan; the CRB conducted a central review, and after the study had been approved by the CRB, investigators at each site obtained permission from their administrator to start the research. Involvement of an ethical review committee at each facility is not required by the Clinical Research Act. The study was also conducted in accordance with the ethical principles, clinical research laws, and relevant notifications stipulated in the Declaration of Helsinki (as revised in 2013).Written informed consent was obtained from each patient after investigators had explained what participation in the MiroCIP study entailed, ensuring that they had the required understanding of the study procedures before agreeing to participation.
: Not applicable.
: SM, TD, TSuzuki, YN, TK, MT, TSuichi, and SKuwabara received lecture fees from Daiichi Sankyo Co., Ltd. SKodama and KS are employees of Daiichi Sankyo Co., Ltd.
